Merck & Co., Inc. $MRK Shares Acquired by Invenio Wealth Partners LLC

Invenio Wealth Partners LLC boosted its holdings in Merck & Co., Inc. (NYSE:MRK) by 63.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,195 shares of the company’s stock after purchasing an additional 2,789 shares during the quarter. Invenio Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $570,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in MRK. Peoples Financial Services CORP. grew its holdings in Merck & Co., Inc. by 0.5% in the 2nd quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock valued at $1,803,000 after buying an additional 122 shares during the period. McLean Asset Management Corp boosted its position in shares of Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after acquiring an additional 125 shares during the last quarter. Cora Capital Advisors LLC grew its holdings in Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock valued at $423,000 after purchasing an additional 125 shares during the period. Saiph Capital LLC increased its position in Merck & Co., Inc. by 3.7% during the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after purchasing an additional 128 shares during the last quarter. Finally, Physician Wealth Advisors Inc. increased its position in Merck & Co., Inc. by 2.9% during the second quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock worth $363,000 after purchasing an additional 128 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Up 0.0%

NYSE MRK opened at $92.94 on Tuesday. The stock has a market cap of $230.69 billion, a PE ratio of 14.32, a P/E/G ratio of 0.95 and a beta of 0.34. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $105.07. The business has a 50 day moving average price of $85.43 and a two-hundred day moving average price of $82.43. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. During the same quarter last year, the firm posted $1.57 earnings per share. The business’s quarterly revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on MRK. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Wells Fargo & Company reduced their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Finally, Scotiabank initiated coverage on Merck & Co., Inc. in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $105.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $104.50.

Insiders Place Their Bets

In related news, EVP David Michael Williams sold 8,614 shares of Merck & Co., Inc. stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the sale, the executive vice president owned 24,578 shares of the company’s stock, valued at $2,054,475.02. The trade was a 25.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.